In patients with classical congenital adrenal hyperplasia, the use of modified-release hydrocortisone may improve biochemical control.
Cross-sex hormone therapy may have a negative effect on lipid profile and glucose levels in transgender men but not in transgender women.
Elevated levels of thyrotropin in patients with a history of chronic heart or renal failure may not always indicate thyroid disease.
Radiofrequency ablation and laser ablation are both safe and very effective for reducing the volume of thyroid nodules.
Researchers identified predictors of biochemical treatment response to antithyroid drugs, specifically methimazole, in patients with Graves disease.
The 8th edition of the American Joint Committee on Cancer staging system does not address disparities in outcomes in differentiated thyroid cancer.
A remote care intervention with carbohydrate restriction demonstrated meaningful improvements in metabolic risk in type 2 diabetes.
Researchers evaluated the efficacy of low-dose denosumab for maintaining bone mineral density in postmenopausal women with osteoporosis.
Acromegaly is associated with an increased risk for mortality from vascular and respiratory disease, but not malignant disease.
Chronic treatment for diabetic cardiomyopathy with the phosphodiesterase-5 inhibitor tadalafil resulted in reductions in cardiac torsion and left ventricular strain in men, but not women, with type 2 diabetes.
Severe depression is associated with higher thyrotropin levels, according to results of a historical cohort study conducted at the University of Utah.
In women with anorexia nervosa, elevated levels of the sulfated form of dehydroepiandrosterone may predict weight gain and higher overall gains in fat mass.
Researchers analyzed diabetes mobile applications to evaluate patient self-management capabilities and the compliance of these apps with diabetes care guidelines.
Kisspeptin might play a role in ovulation and successful pregnancy in patients with infertility who undergo in vitro fertilization.
Switching from daily human growth hormone to once-weekly TransCon growth hormone treatment resulted in similar safety and efficacy outcomes in pediatric patients.